For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024

1. Ophthalmic Drugs Market Forecast
2014-2024
Prospects for Leading Companies
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.

2. www.visiongain.com
Contents
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Eye: An Overview of Its Structure and Function
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: the ‘Silent Thief of Sight’
2.5.1 A Classification of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
1. Report Overview
2. Introduction to Ophthalmic Drugs

3. www.visiongain.com
Contents
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors for AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome

4. www.visiongain.com
Contents
2.12 Phases of Clinical Trials
2.13 Scope of this Report
2.14 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2014-2024
3.1 The World Ophthalmic Drugs Market in 2013
3.1.1 Leading Ophthalmic Drugs
3.1.2 Leading Companies in the Ophthalmic Drugs Market
3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024
3.3 Retinal Disorder Drugs Lead the World Ophthalmic Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.4.1 World Ophthalmic Drugs Market: Drivers and Restraints 2014-2024
4. Leading National Markets 2014-2024
4.1 Geographical Breakdown of the World Ophthalmic Drugs Market
4.2 World Ophthalmic Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Ophthalmic Drugs Market 2014-2024
4.3.1 US Ophthalmic Drugs Market Forecast 2014-2024
4.3.2 US Ophthalmic Drugs Market: Trends and Developments
4.3.2.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2.2 A US Biosimilars Market?
4.4 Japanese Ophthalmic Drugs Market 2014-2024
3. Ophthalmic Drugs: World Market 2014-2024
4. Leading National Markets 2014-2024

5. www.visiongain.com
Contents
4.4.1 Japanese Ophthalmic Drugs Market Forecast 2014-2024
4.4.2 Japanese Ophthalmic Drugs Market: Trends and Developments
4.4.2.1 The Cost of Treatment in Japan
4.5 Chinese Ophthalmic Drugs Market 2014-2024
4.5.1 Chinese Ophthalmic Drugs Market Forecast 2014-2024
4.5.2 Chinese Ophthalmic Drugs Market: Trends and Developments
4.5.2.1 Expansion of Healthcare Coverage and Reimbursement
4.5.2.2 Price Controls and the Anhui Model
4.6 EU5 Ophthalmic Drugs Market 2014-2024
4.6.1 German Ophthalmic Drugs Market Forecast 2014-2024
4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024
4.6.3 UK Ophthalmic Drugs Market Forecast 2014-2024
4.6.4 Italian Ophthalmic Drugs Market Forecast 2014-2024
4.6.5 Spanish Ophthalmic Drugs Market Forecast 2014-2024
4.7 Brazilian Ophthalmic Drugs Market 2014-2024
4.7.1 Brazilian Ophthalmic Drugs Market Forecast 2014-2024
4.7.2 Brazilian Ophthalmic Drugs Market: Trends and Developments
4.7.2.1 Increasing Access to Medicines
4.8 Russian Ophthalmic Drugs Market 2014-2024
4.8.1 Russian Ophthalmic Drugs Market Forecast 2014-2024
4.8.2 Russian Ophthalmic Drugs Market: Trends and Developments
4.8.2.1 Pharma2020, Healthcare and Industry Reform
4.9 Indian Ophthalmic Drugs Market 2014-2024
4.9.1 Indian Ophthalmic Drugs Market Forecast 2014-2024

6. www.visiongain.com
Contents
4.9.2 Indian Ophthalmic Drugs Market: Trends and Developments
4.9.2.1 Drug Prices Control Order 2013
4.9.2.2 Expansion of Healthcare Provision
4.10 Mexican Ophthalmic Drugs Market 2014-2024
4.10.1 Mexican Ophthalmic Drugs Market Forecast 2014-2024
4.10.2 Mexican Ophthalmic Drugs Market: Trends and Developments
4.10.2.1 Lupin Acquires Laboratorios Grin, Entering the Mexican Market
4.10.2.2 Seguro Popular: Mexican Healthcare Reform
4.10.2.3 International Interest in Mexico
5. Retinal Disorder Drugs Market 2014-2024
5.1 Retinal Disorder Drugs: the Rise of Anti-VEGF Therapy
5.2 Leading Retinal Disorder Drugs in 2013
5.3 Retinal Disorder Drugs: Market Forecast 2014-2024
5.4 Market Share of Leading Retinal Disorder Drugs to 2024
5.5 Retinal Disorder Drugs: Trends and Developments
5.5.1 Lucentis Dominates the Retinal Disorder Drugs Market
5.5.2 Roche and Novartis Fined Over Lucentis-Avastin Collusion
5.5.3 Requiring Avastin Use in AMD?
5.5.4 Novartis Licenses Ophthotech’s Fovista
5.5.5 Jetrea Launch Disappoints Analysts
5.5.6 Conbercept Approved in China
5.5.7 Drug/Device Combination Products Entering the Market
5.5.8 Advances in Regenerative Medicine
5. Retinal Disorder Drugs Market 2014-2024

7. www.visiongain.com
Contents
5.6 Lucentis (ranibizumab, Roche/Novartis)
5.6.1 Lucentis: Sales Forecast 2014-2024
5.6.2 Less Frequent Dosing Approved in US
5.6.3 New Indications for Lucentis
5.6.4 Lucentis/Fovista Combination Therapy?
5.7 Eylea (aflibercept, Regeneron/Bayer/Santen)
5.7.1 Eylea: Sales Forecast 2014-2024
5.7.2 The Comparative Efficacy of Eylea
5.7.3 Combination Therapy with Eylea and a PDGFR-beta Inhibitor
5.8 Avastin (bevacizumab, Roche)
5.8.1 Avastin: Sales Forecast 2014-2024
5.8.2 Compounding Pharmacies and Safety Risks
5.9 Visudyne (verteporfin, Valeant/Novartis)
5.9.1 Visudyne: Sales Forecast 2014-2024
5.10 Jetrea (ocriplasmin, ThromboGenics/Novartis)
5.10.1 Jetrea: Sales Forecast 2014-2024
5.10.2 Potential Acquisition of ThromboGenics?
5.10.3 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
5.11 Other Retinal Disorder Drugs
5.11.1 Iluvien (fluocinolone implant, Alimera Sciences)
5.11.2 Ozurdex (dexamethasone implant, Allergan)
6. Allergic, Inflammatory and Infective Drugs Market 2014-2024
6.1 Allergic, Inflammatory and Infective Drugs: Introduction
6. Allergic, Inflammatory and Infective Drugs Market 2014-2024

8. www.visiongain.com
Contents
6.2 Allergic, Inflammatory and Infective Drugs: Submarket Breakdown
6.3 Leading Allergic, Inflammatory and Infective Drugs in 2013
6.4 Allergic, Inflammatory and Infective Drugs: Market Forecast 2014-2024
6.5 Market Share of Leading Allergic, Inflammatory and Infective Drugs to 2024
6.6 Allergic, Inflammatory and Infective Drugs: Trends and Developments
6.6.1 Growth Prospects in 2014-2024
6.6.2Lupin Launches Generic Zymaxid
6.6.3 New Topical NSAIDs Launched: Prolensa and Ilevro
6.7 Patanol and Pataday (olopatadine, Alcon)
6.7.1 Patanol: Sales Forecast 2014-2024
6.7.2 Pataday: Sales Forecast 2014-2024
6.7.3 Generic Competition for Patanol/Pataday?
6.8 Vigamox (moxifloxacin, Alcon)
6.8.1 Vigamox: Sales Forecast 2014-2024
6.8.2 Generic Challenges to Vigamox
6.8.3 Moxeza: A Next-Generation Form of Vigamox
6.9 TobraDex (tobramycin/dexamethasone, Alcon)
6.9.1 TobraDex: Sales Forecast 2014-2024
6.9.2 TobraDex ST (Alcon/Novartis)
6.10 Bromday (bromfenac, Valeant)
6.10.1 Bromday: Sales Forecast 2014-2024
6.10.2 Prolensa: A New Formulation of Bromfenac
6.10.3 Competition from Ilevro/Nevanac
6.11 Cravit (levofloxacin, Santen)

9. www.visiongain.com
Contents
6.11.1 Cravit: Sales Forecast 2014-2024
6.12 Acular (ketorolac, Allergan)
6.12.1 Acular: Sales Forecast 2014-2024
6.13 AzaSite (azithromycin, Akorn)
6.13.1 AzaSite: Sales Forecast 2014-2024
7. Glaucoma Drugs Market 2014-2024
7.1 Glaucoma: Prostaglandin Analogues Lead the Market
7.2 Leading Glaucoma Drugs in 2013
7.3 Glaucoma Drugs: Market Forecast 2014-2024
7.4 Market Share of Leading Glaucoma Drugs to 2024
7.5 Glaucoma Drugs: Trends and Developments
7.5.1 Revenues Threatened by Patent Expiration
7.5.2 Preservative-Free Formulation Trends
7.5.3 Innovation in Treatments for Glaucoma
7.5.4 Simbrinza Launched as First Beta-Blocker-Free Combination
7.6 Lumigan and Ganfort (bimatoprost, Allergan)
7.6.1 Lumigan and Ganfort: Sales Forecast 2014-2024
7.7 Xalatan and Xalacom (latanoprost, Pfizer)
7.7.1 Xalatan/Xalacom: Sales Forecast 2014-2024
7.8 Travatan/Travatan Z and DuoTrav (travoprost, Novartis)
7.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024
7.9 Alphagan/Alphagan P and Combigan (brimonidine, Allergan)
7.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024
7. Glaucoma Drugs Market 2014-2024

10. www.visiongain.com
Contents
7.10 Trusopt and Cosopt/Cosopt PF (dorzolamide, Merck)
7.10.1 Trusopt: Sales Forecast 2014-2024
7.10.2 Cosopt and Cosopt PF: Sales Forecast 2014-2024
7.11 Azopt (brinzolamide, Novartis)
7.11.1 Azopt: Sales Forecast 2014-2024
7.12 Tapros (tafluprost, Santen)
7.12.1 Tapros/Taflotan: Sales Forecast 2014-2024
7.13 Zioptan (tafluprost, Akorn)
7.13.1 Zioptan: Sales Forecast 2014-2024
8. Dry Eye Drugs Market 2014-2024
8.1 Dry Eye: Introduction
8.2 Leading Dry Eye Drugs in 2013
8.3 Dry Eye Drugs: Market Forecast 2014-2024
8.4 Market Share of Leading Dry Eye Drugs to 2024
8.5 Dry Eye Drugs: Trends and Developments
8.5.1 Will Generic Restasis Launch in 2014?
8.5.2 Intensive Research Focus on Dry Eye
8.5.3 Improving Diagnostic Tools
8.6 Restasis (ciclosporin, Allergan)
8.6.1 Restasis: Sales Forecast 2014-2024
8.7 Refresh Brand Products (Allergan)
8.7.1 Refresh Brand Products: Sales Forecast 2014-2024
8.8 Hyalein (hyaluronic acid, Santen)
8. Dry Eye Drugs Market 2014-2024

11. www.visiongain.com
Contents
8.8.1 Hyalein: Sales Forecast 2014-2024
8.9 Diquas (diaquafosol, Santen)
8.9.1 Diquas: Sales Forecast 2014-2024
8.10 Other Ophthalmic Drugs
8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)
8.10.2 Hetlioz: Sales Forecast 2014-2024
9. Leading Companies in the Ophthalmic Drugs Market
9.1 Novartis (Alcon)
9.1.1 Novartis: Ophthalmic Drugs Portfolio
9.1.2 Novartis: Sales Forecast 2014-2024
9.1.3 Novartis: Products in Development
9.1.4 Novartis: Recent Developments
9.1.4.1 Novartis Restructures Following Strategic Review
9.1.4.2 Novartis Licenses Ophthothech’s Fovista
9.2 Allergan
9.2.1 Allergan: Ophthalmic Drugs Portfolio
9.2.2 Allergan: Sales Forecast 2014-2024
9.2.3 Allergan: Products in Development
9.2.3.1 Novadur (Intravitreal Brimonidine Implant)
9.2.4 Allergan: Recent Developments
9.2.4.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for
Diabetic Macular Oedema
9.2.4.2 Prospects for Generic Restasis?
9. Leading Companies in the Ophthalmic Drugs Market

12. www.visiongain.com
Contents
9.2.4.3 Allergan Rejects Valeant Bid
9.2.4.4 Allergan Considering Acquiring Shire?
9.3 Roche
9.3.1 Roche: Ophthalmic Drugs Portfolio
9.3.1.1 Lucentis: US Sales Forecast 2014-2024
9.3.2 Roche: Sales Forecast 2014-2024
9.3.3 Roche: Products in Development
9.4 Valeant
9.4.1 Valeant: Ophthalmic Drugs Portfolio
9.4.2 Valeant: Sales Forecast 2014-2024
9.4.3 Valeant: Products in Development
9.4.4 Valeant: Recent Developments
9.4.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
9.4.4.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals
9.5 Regeneron
9.5.1 Regeneron: Ophthalmic Drugs Portfolio
9.5.2 Regeneron: Sales Forecast 2014-2024
9.5.3 Regeneron: Products in Development
9.5.4 Regeneron: Recent Developments
9.5.4.1 FDA Approves Zaltrap (aflibercept)
9.5.4.2 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
9.6 Santen
9.6.1 Santen: Ophthalmic Drugs Portfolio
9.6.2 Santen: Sales Forecast 2014-2024

13. www.visiongain.com
Contents
9.6.3 Santen: Products in Development
9.6.4 Santen: Recent Developments
9.6.4.1 Santen Acquires Novagali Pharma
9.6.4.2 Santen Launches Alesion in Japan
9.6.4.3 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.7 Pfizer
9.7.1 Pfizer: Ophthalmic Drugs Portfolio
9.7.1.1 Macugen (Valeant/Pfizer)
9.7.2 Pfizer: Sales Forecast 2014-2024
9.7.3 Pfizer: Products in Development
9.7.4 Pfizer: Recent Developments
9.7.4.1 Pfizer Attempts to Acquire AstraZeneca
9.8 Merck
9.8.1 Merck: Ophthalmic Drugs Portfolio
9.8.2 Merck: Sales Forecast 2014-2024
9.8.3 Merck: Products in Development
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2014-2024
9.10 Senju
9.10.1 Senju: Ophthalmic Drugs Portfolio
9.10.2 Senju: Sales Forecast 2014-2024
9.10.3 Senju: Products in Development
9.10.3.1 Y-39983 (SNJ-1656)

14. www.visiongain.com
Contents
9.10.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs Pipeline Analysis 2014-2024
10.1 The Ophthalmic Drugs Pipeline: Richest in Retinal Disorder Agents
10.2 The Retinal Disorders Pipeline
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 Compaq Sipp (conbercept, Chengdu Kanghong Pharmaceutical)
10.3.2 Lipidil (fenofibrate, Abbott)
10.3.3 Iluvien (fluocinolone, Alimera)
10.4 Retinal Disorders: Phase 3 Pipeline
10.4.1 Fovista and Zimura (Ophthotech)
10.4.2 MC-1101 (hydralazine, MacuCLEAR)
10.4.3 Tandospirone (serotonin 1A agonist, Alcon)
10.4.4 UF-021 (unoprostone, R-Tech Ueno)
10.5 Retinal Disorders: Phase 2 Pipeline
10.5.1 AKB-9778 (Tie2 activator, Aerpio Therapeutics)
10.5.2 ALG-1001 (Integrin peptide therapy, Allegro/Senju)
10.5.3 AGN150998 and MP0260 (Anti-VEGF DARPins, Allergan)
10.5.4 AGN208397 (beclomethasone, Allergan)
10.5.5 CPC-551 (Colby Pharmaceutical)
10.5.6 Darapladib and GSK933776 (GSK)
10.5.7 ESBA1008 (anti-VEGF mAb, Alcon)
10.5.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA, iCo Therapeutics)
10. Ophthalmic Drugs Pipeline Analysis 2014-2024

15. www.visiongain.com
Contents
10.5.9 iSONEP (sonepcizumab, Lpath)
10.5.10 Lampalizumab (anti-Factor D Fab, Roche)
10.5.11 LFG316 (anti-C5 mAb, Novartis)
10.5.12 Novadur (Intravitreal brimonidine implant, Allergan)
10.5.13 Optina (danazol, Ampio Pharmaceuticals)
10.5.14 PF-655 (synthetic siRNA, Quark/Pfizer)
10.5.15 Premiplex (protein replacement therapy, Shire)
10.5.16 Renexus (ciliary neurotrophic factor, Neurotech)
10.5.17 Squalamine (anti-angiogenic drug, OHR Pharmaceutical)
10.5.18 Zybrestat (fosbretabulin, Oxigene/Symphony VIDA)
10.6 Retinal Disorders: Phase 1 and Preclinical Pipeline
10.6.1 BDM-E (BioDiem)
10.6.2 NADPH Oxidase Inhibitors (Alimera)
10.6.3 NS2 (aldehyde trap, Aldeyra Therapeutics)
10.6.4 PAN-90806 (topical VEGF inhibitor, PanOptica)
10.6.5 Plasma Kallikrein Inhibitors (KalVista)
10.6.6 QLT091001 (synthetic retinoid, QLT)
10.7 Allergic, Inflammatory and Infective Drugs: Phase 3 Pipeline
10.7.1 EGP-437 (dexamethasone, EyeGate)
10.7.2 IBI-10090 and IBI-20089 (Icon Bioscience)
10.7.3 LE-MPP (loteprednol etabonate, Kala)
10.8 Allergic, Inflammatory and Infective Drugs: Phase 2 Pipeline
10.8.1 CF101 (adenosine A3 receptor agonist, Can-Fite BioPharma and OphthaliX)
10.8.2 FST-100 (povidone-iodine/dexamethasone, ForeSight Biotherapeutics)

16. www.visiongain.com
Contents
10.8.3 NVC-422 (auriclosene, NovaBay)
10.8.4 Sarilumab (Regeneron)
10.8.5 V404 PDS (ForSight VISION4)
10.9 Allergic, Inflammatory and Infective Drugs: Phase 1 and Preclinical Pipeline
10.9.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
10.10 Glaucoma: Phase 2 and Phase 3 Pipeline
10.10.1 Latanoprostene Bunod (BOL-303259-X, Valeant)
10.10.2 AMA0076 (ROCK inhibitor, Amakem)
10.10.3 Rhopressa (AR-13324; ROCK and NET inhibitor) and Roclatan (PG324; ROCK
inhibitor), Aerie Pharmaceuticals
10.11 Glaucoma: Phase 1 and Preclinical Pipeline
10.12 Dry Eye: Phase 3 Pipeline
10.12.1 EBI-005 (IL-1R antagonist, Eleven Biotherapeutics)
10.12.2 Lifitegrast (integrin antagonist, Shire)
10.12.3 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)
10.12.4 SI-614 (modified hyaluronate, Seikagaku)
10.13 Dry Eye: Phase 2 Pipeline
10.13.1 ESBA105 (TNF-alpha antibody, Novartis/Alcon)
10.13.2 Kineret (anakinra: IL-1 receptor antagonist, Amgen/Sobi)
10.14 Other Ophthalmic Drugs Pipeline
10.14.1 Brimonidine for Eye Whitening (Valeant)
10.14.2 GS-101 (aganirsen, Gene Signal)
10.14.3 Omidria (phenylephrine/ketorolac, Omeros)

17. www.visiongain.com
Contents
11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024
11.1 SWOT Analysis of the Ophthalmic Drugs Market
11.2 Strengths
11.2.1 Advances in Drug Delivery Technologies
11.2.2 Support for Reimbursement
11.2.3 Strong R&D Pipeline
11.2.3.1 Gene Therapy and RNA Interference Technology
11.2.3.2 New Ophthalmic Therapeutic Applications for Drugs
11.2.3.3 Development of Neuroprotective Anti-Glaucoma Medications
11.2.3.4 Working with Biomarkers
11.3 Weaknesses
11.3.1 Patient Adherence to Treatment
11.3.2 High Treatment Burden
11.3.3 Under-Diagnosis and Under-Treatment
11.4 Opportunities
11.4.1 Increasing Disease Prevalence
11.4.1.1 Ageing of the World Population
11.4.1.2 Increasing Prevalence of Eye Diseases and Diabetes
11.4.1.3 Glaucoma and Retinal Disorders Will Have the Most-Marked Increases in
Prevalence
11.4.2 Unmet Clinical Need in Many Disease Areas
11.4.3 Higher Growth in Emerging Markets
11.4.4 Sustained-Release Ocular Implants
11.5 Threats
11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024

18. www.visiongain.com
Contents
11.5.1 Generic Competition
11.5.2 Price Regulation
11.5.3 Biosimilars
11.5.4 Increasing R&D Costs
11.6 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
11.6.1 Rivalry Among Competitors [Medium]
11.6.2 Threat of New Entrants [Low]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11.6.5 Threat of Substitutes [Medium]
12. Research Interviews
12.1 Interview with Cathy Yelf, Head of External Relations, Macular Society, Andover,
Hampshire, UK
12.1.1 The Work of the Macular Society
12.1.2 Developments in Treating AMD
12.1.3 Lucentis, Eylea and Avastin
12.1.4 Developments in Diagnosis of Eye Conditions
12.1.5 Unmet Needs in AMD
12.1.6 The Future of the Ophthalmic Drugs Market?
12.2 Interview with the Royal National Institute of Blind People (RNIB), London, UK
12.2.1 The Work of RNIB
12.2.2 Developments in Ophthalmology
12.2.3 Unmet Needs in Glaucoma and AMD
12. Research Interviews

19. www.visiongain.com
Contents
12.2.4 The Future of the Ophthalmic Drugs Market?
12.3 Interview with Dr Charles Wykoff, Retina Consultants of Houston, Texas, US
12.3.1 Developments in Ophthalmology
12.3.2 Unmet Needs in Ophthalmology
12.3.3 Regulatory Issues in the US Market
12.3.4 The Future of the Ophthalmic Drugs Market?
12.4 Interview with Professor Manju Subramanian, Associate Professor, Department of
Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, US
12.4.1 Developments in Ophthalmology
12.4.2 Unmet Needs in Ophthalmology
12.4.3 Treatments for Glaucoma, AMD and Dry Eye
12.4.4 Lucentis, Eylea and Avastin
12.4.5 Jetrea for Retinal Disorders
12.4.6 The Future of the Ophthalmic Drugs Market?
12.5 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US
12.5.1 Commercialising Hetlioz
12.5.2 Future Prospects for Vanda
12.6 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University
College London, UK
12.6.1 On the Role of VEGF in Retinal Disorders
12.6.2 On Candidate Molecule E10030
12.6.3 On Candidate Molecule JSM 6427
12.6.4 On New Sustained Release Formulations
12.6.5 On Delta-Notch Signalling
12.6.6 Potential Clinical Crossovers Between Ophthalmology and Oncology

20. www.visiongain.com
Contents
12.6.7 Commercial and Clinical Possibilities in the Ophthalmology Market
12.6.8 On the Possibilities of Research into the Endothelial Fenestra
12.7 Expert Interview 7: Authority from a Company in the Industry (Views Provided
Anonymously)
12.7.1 Key Unmet Needs
12.7.2 Challenges Facing the Ophthalmic Sector
12.7.3 On Current Ophthalmic Treatments and Their Effectiveness
12.7.4 On Opportunities in the Ophthalmic Sector
12.8 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor,
Michigan, USA
12.8.1 The Optogenetic Approach to Vision Restoration
12.8.2 Choosing Disease Targets and Delivery Vectors
12.8.3 The Regulatory Picture
12.8.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
12.8.5 The Next Ten Years for Gene Therapy
12.9 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA
12.9.1 MC-1101: Identifying and Treating Chiou Syndrome
12.9.2 Preventing Dry AMD Progression
12.9.3 Treating the Root Cause of Dry AMD
12.9.4 Phase 3: Endpoints and Prospects for MC-1101
12.10 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida,
USA
12.10.1 The Impact of Eylea
12.10.2 The Comparative Dosing Schedules of Eylea and Lucentis
12.10.3 Patient Transitioning to Eylea: Salvage Switching

21. www.visiongain.com
Contents
12.10.4 Avastin after the CATT Study
12.10.5 Prospects for Eylea in Other Indications and Combinations
12.10.6 Future Possibilities in Wet AMD Treatment
13. Conclusions
13.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
13.2 The World Ophthalmic Drugs Market in 2013
13.2.1 Current Leading Ophthalmic Drugs Segments
13.2.2 Leading Ophthalmic Drugs Products
13.2.3 Leading Ophthalmic Drugs Companies
13.2.4 Leading National Markets
13.3 World Ophthalmic Drugs Market Forecast 2014-2024
13.4 Ophthalmic Drugs Late-Stage Pipeline
13.5 The Future of the Ophthalmic Drugs Market?
13.5.1 Increasing Revenue Concentration among Specialist Companies
13.5.2 The Rise of Generics
13.5.3 Small Companies Can Have a Big Impact
13.5.4 What Will Succeed in the Ophthalmic Drugs Market?
13. Conclusions

22. www.visiongain.com Page 101
Ophthalmic Drugs Market Forecast 2014-2024:
Prospects for Leading Companies
highest in Europe, a trend that will contribute to slowing pharmaceutical sales growth. The
tendering system and other cost-cutting measures will also restrain growth.
4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024
Visiongain estimates that in 2013, the French ophthalmic drugs market reached $724m,
representing 3.7% of the world market. In 2014 the French market will increase to $742m, up 2.5%
on 2013. Table 4.9 and Figure 4.11 show visiongain’s forecast for the French ophthalmic drugs
market over 2013-2024.
Table 4.9 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2013-2024
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
France ($m) 724 742 760 780 795 814 831 850 868 888 912 943
Annual Growth Rate (%) 2.5 2.4 2.6 1.9 2.4 2.0 2.3 2.2 2.3 2.7 3.3
CAGR (%, 2013-2018
and 2018-2024)
2.4 2.5
CAGR (%, 2013-2024) 2.4
Figure 4.11 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%),
2013-2024
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0
100
200
300
400
500
600
700
800
900
1,000
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales($m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014

23. www.visiongain.com Page 192
Ophthalmic Drugs Market Forecast 2014-2024:
Prospects for Leading Companies
revenues will reach $238m in 2024, representing a CAGR of 6.1% over 2018-2024 and an overall
CAGR of 11.1% over 2013-2024.
Table 8.7 and Figure 8.8 show visiongain’s estimates of Diquas revenues over 2013-2024.
Table 8.7 Santen: Diquas Revenue ($m), AGR (%), CAGR (%), 2013-2024
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Diquas ($m) 75 97 117 134 150 167 181 196 208 219 228 238
Annual Growth Rate (%) 30.0 20.0 15.0 12.0 11.1 8.5 8.0 6.5 5.2 4.2 4.0
CAGR (%, 2013-2018
and 2018-2024)
17.4 6.1
CAGR (%, 2013-2024) 11.1
Figure 8.8 Santen: Diquas Revenue ($m), AGR (%), 2013-2024
8.10 Other Ophthalmic Drugs
8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)
Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, DC. It focuses on
developing drugs for treating CNS disorders, such as its other available drug Fanapt (iloperidone)
for schizophrenia. Hetlioz (tasimelteon) is an oral drug for the treatment of non-24-hour disorder, a
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
0
50
100
150
200
250
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales($m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014

24. www.visiongain.com Page 224
Ophthalmic Drugs Market Forecast 2014-2024:
Prospects for Leading Companies
9.7.2 Pfizer: Sales Forecast 2014-2024
Table 9.15 and Figure 9.8 show visiongain’s estimates of Pfizer’s ophthalmic drug revenues over
2013-2024.
Table 9.15 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Pfizer ($m) 595 469 399 281 240 228 226 231 237 244 251 259
Annual Growth Rate (%) -21.2 -14.8 -29.5 -14.7 -4.9 -1.0 1.9 2.9 2.9 2.9 2.9
CAGR (%, 2013-2018
and 2018-2024)
-17.4 2.1
CAGR (%, 2013-2024) -7.3
Figure 9.8 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2013-2024
Pfizer’s ophthalmic drug revenues peaked in 2010, reaching an estimated $1,758m largely due to
sales of Xalatan and Xalacom. However, revenues have since fallen to reach $595m in 2013, a
CAGR of -30.3% over 2010-2013 mirroring the decline in revenues from Xalatan/Xalacom. This
decline was primarily due to generic competition for Xalatan/Xalacom, which lost patent protection
in all major pharmaceutical markets. Xalatan lost exclusivity in the US in March 2011 and Pfizer
further lost exclusivity for Xalatan and Xalacom in 15 major European markets in January 2012.
-35.0
-30.0
-25.0
-20.0
-15.0
-10.0
-5.0
0.0
5.0
0
100
200
300
400
500
600
700
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales($m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014